Spectrum Pharmaceuticals cuts 75% of R&D Jobs after FDA declined Approval For cancer drug

Spectrum Pharmaceuticals Cuts 75% of R&D Jobs After FDA Declined Approval For Cancer Drug

Spectrum Pharmaceuticals, Inc. a biopharmaceutical company focused on acquiring, developing, and commercializing targeted oncology therapies says it will reduce three-fourths of…